60 Degrees Pharmaceuticals’ (SXTP) “Sell (E+)” Rating Reiterated at Weiss Ratings

60 Degrees Pharmaceuticals (NASDAQ:SXTP)‘s stock had its “sell (e+)” rating reissued by stock analysts at Weiss Ratings in a research note issued on Saturday,Weiss Ratings reports.

Separately, HC Wainwright restated a “neutral” rating on shares of 60 Degrees Pharmaceuticals in a research note on Friday, January 10th.

60 Degrees Pharmaceuticals Price Performance

Shares of 60 Degrees Pharmaceuticals stock opened at $0.83 on Friday. The business has a fifty day simple moving average of $1.19 and a two-hundred day simple moving average of $1.02. 60 Degrees Pharmaceuticals has a 1 year low of $0.70 and a 1 year high of $11.01. The company has a market capitalization of $1.90 million, a price-to-earnings ratio of -0.08 and a beta of 4.40.

Insider Activity

In other 60 Degrees Pharmaceuticals news, CEO Geoffrey S. Dow bought 35,823 shares of 60 Degrees Pharmaceuticals stock in a transaction dated Monday, December 9th. The stock was bought at an average price of $1.27 per share, with a total value of $45,495.21. Following the completion of the transaction, the chief executive officer now owns 94,580 shares in the company, valued at $120,116.60. The trade was a 60.97 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Over the last quarter, insiders have bought 66,372 shares of company stock valued at $82,410. 10.27% of the stock is owned by insiders.

About 60 Degrees Pharmaceuticals

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.